Lumentum股票讨论区

Matthew Sepe's recent sale suggests he considered a lower price fair, questioning the higher valuation of shares. Despite significant insider ownership indicating alignment, the absence of insider purchases and history of sales call for caution before buying Lumentum Holdings shares.

Despite Lumentum Holdings' recent revenue drop, the market may anticipate a reversal, justifying its high P/S ratio. The company's projected revenue growth, surpassing the Communications industry, could be maintaining share price and shareholder confidence.

The company's balance sheet is strained due to debt and EBIT level loss. Its use of debt is risky, given it burned through US$9.7m of cash last year.

Lumentum Holdings is being seen as a valuable investment opportunity due to its future outlook and the fact that it is being undervalued by the stock market. The optimistic growth projections have not yet been fully accounted for in the share price.

Bristol Myers may bolster its treatments portfolio with Karuna acquisition. Ansys' possible undervaluation hinted by takeover speculation. ASML's gear shipment to Intel viewed positively, fostering quicker semiconductor production. Lumentum's upgrade signals bullish prospects for 2024.

Craig-Hallum analysts predict that the telecom market, a strong base for Lumentum, is set to bottom out. Recent Cloud Light acquisition is seen to boost Lumentum's footprint in the affluent datacom market. Reduced Apple exposure, previously a stumbling block, is now seen as a positive stride.

Investors are urged to examine warning signs in Lumentum Holdings' performance. The rise in CEO pay, despite the company's poor performance, could be a contentious issue at the upcoming AGM.

Concerns arise over the riskiness of a company unable to profit at EBIT level, despite a 3.2% revenue increase. Its $132 million loss and heavy debt load allude to a shaky investment.